



7-17-06

IFW ✓

Express Mail No.: EV475142754US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Zeldis

Confirmation No.: 9771

Application No.: 10/534,325

Group Art Unit: 1614

Filed: May 5, 2005

Examiner: Gembeh, Shirley V

For: METHODS AND COMPOSITIONS  
USING SELECTIVE CYTOKINE  
INHIBITORY DRUGS FOR THE  
TREATMENT AND  
MANAGEMENT OF CANCERS  
AND OTHER DISEASES

Attorney Docket No.: 9516-207-999

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references **C66** to **C73** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **C66** to **C73** are provided herewith.


Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicant estimates that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 14, 2006

	(Reg. No.)
By: Yeah-Sil Moon	52,042
For: Anthony M. Insogna	35,203
JONES DAY	
222 East 41 <sup>st</sup> Street	
New York, New York 10017-6702	
(212) 326-3939	



Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
 (Use several sheets if necessary)

ATTY DOCKET NO.

9516-207-999

APPLICATION NO.

10/534,325

APPLICANT:

Zeldis

FILING DATE:

May 5, 2005

ART UNIT: CONF. NO.:

1614

9771

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
	C66	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673
	C67	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437
	C68	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966
	C69	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078
	C70	MARRIOTT et al., 2001, "Immunotherapeutic and antitumor potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8
	C71	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84
	C72	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," Br. J. Haematol. 124(3):366-375
	C73	ZELDIS et al., 2003, "Potential new therapeutics for Waldenstrom's macroglobulinemia," Semin. Oncol. 30(2):275-281

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.